^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Biliary Tract Cancer
    Drug:capecitabine (Thymidylate synthase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ASCO.org
    Excerpt:
    Patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months (Type: Evidence based; Benefits outweigh harms; Evidence quality: Intermediate; Strength of recommendation: Moderate).
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Biliary Tract Cancer: Other Recommended Regimens…Single agents: Capecitabine